Get the Stockscreener App
0.00
100.00%
-53.01
After Hours:
53.02
53.02
+
Soleno Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
See More
Previous Close:
$53.01
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$2.76B
Revenue:
$285.01M
Net Income/Loss:
$95.63M
P/E Ratio:
0.00
EPS:
1.762
Net Cash Flow:
$105.42M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$72.99
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
0.00 | 2.76B | 285.01M | 95.63M | 105.42M | 1.762 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-07-25 | Initiated | Goldman | Buy |
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Stocktwits
Soleno (SLNO) Earnings Reading: The EPS Result Is Below Expectation in the Latest Reading ; Share Performance Is Not Yet AvailableEarnings Seasonality - Vinanet
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect - ACCESS Newswire
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths - The Business Journals
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Wellington reports 0.0% stake in Soleno Therapeutics (SLNO) in amended 13G - Stock Titan
Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy - insights.citeline.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therap - The National Law Review
Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact - Stock Titan
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results - TradingView
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Neurocrine executive who led $2.9B Soleno deal gets new role - Stock Titan
Trading Systems Reacting to (SLNO) Volatility - Stock Traders Daily
2026-07-16 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect | Press Release - Stockhouse
2026-07-14 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Connect | Press Release - Stockhouse
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating A Stable Path In Biotechnology - DirectorsTalk Interviews
Price to earnings forward of Soleno Therapeutics Inc – LS:A3DS0P - TradingView
Soleno Therapeutics 24 Hour Deadline Alert: Kahn Swick & Foti, LL - The National Law Review
2026-07-09 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation | Press Release - Stockhouse
Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo
Soleno Therapeutics (SLNO) Cantor Global Healthcare Conference 2025 Summary - Quartr
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Soleno Therapeutics (SLNO) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
Soleno Therapeutics (SLNO) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr
Soleno Therapeutics (SLNO) Q4 2025 earnings summary - Quartr
Soleno Therapeutics (SLNO) Jefferies London Healthcare Conference 2024 Summary - Quartr
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Steady Performance with Limited Upside in the Biotech Sector - DirectorsTalk Interviews
Soleno Therapeutics Inc. Investors with Substantial Losses Have O - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno (NBIX) - Seeking Alpha
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - The Globe and Mail
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Stable Horizon with Strong Cash Reserves - DirectorsTalk Interviews
How Soleno Therapeutics Inc. (SLNO) Affects Rotational Strategy Timing - Stock Traders Daily
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirt - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect - ACCESS Newswire
2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect | Press Release - Stockhouse
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating the Biotech Sector with a Strong Free Cash Flow - DirectorsTalk Interviews
Soleno Therapeutics Inc (SLNO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Soleno Therapeutics Inc (SLNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
2026-06-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect | Press Release - Stockhouse
Soleno Therapeutics Inc (SLNO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Soleno Therapeutics presents new Vykat XR data at ENDO - The Pharma Letter
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):